Delivering a Next Generation Platform for Antibody Drug Discovery


Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced nonexclusive licensing of the AlivaMab Mouse technology to multiple top global pharmaceutical companies and continues making the AlivaMab Mouse available via non-exclusive licenses.


Year Invested: 2009
Location: San Francisco, Calif.
Visit: www.ablexis.com

Recent News

February 14, 2017
Ablexis Announces Perpetual License Agreement for AlivaMab Mouse with Janssen

July 20, 2016
Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma

March 22, 2016
Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma

Read More News

Associated Team Members

Cary Pfeffer, M.D.
Partner